Blurbs

Analysts Offer Insights on Healthcare Companies: Moderna (MRNA), Genmab (GMAB) and Adaptimmune Therapeutics (ADAP)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Moderna (MRNAResearch Report), Genmab (GMABResearch Report) and Adaptimmune Therapeutics (ADAPResearch Report).

Moderna (MRNA)

Brookline Capital Markets analyst Leah R. Cann maintained a Buy rating on Moderna today and set a price target of $506.00. The company’s shares closed last Monday at $179.50.

According to TipRanks.com, Cann is a 1-star analyst with an average return of -1.0% and a 43.4% success rate. Cann covers the Healthcare sector, focusing on stocks such as Crispr Therapeutics AG, Syros Pharmaceuticals, and Intellia Therapeutics.

Currently, the analyst consensus on Moderna is a Moderate Buy with an average price target of $196.55, a 16.1% upside from current levels. In a report issued on November 3, Cowen & Co. also maintained a Buy rating on the stock with a $130.00 price target.

See Insiders’ Hot Stocks on TipRanks >>

Genmab (GMAB)

In a report released today, Matthew Harrison from Morgan Stanley maintained a Sell rating on Genmab, with a price target of $34.00. The company’s shares closed last Monday at $42.50, close to its 52-week high of $43.98.

According to TipRanks.com, Harrison is a 4-star analyst with an average return of 6.5% and a 50.7% success rate. Harrison covers the Healthcare sector, focusing on stocks such as Cerevel Therapeutics Holdings, Zentalis Pharmaceuticals, and BioMarin Pharmaceutical.

Genmab has an analyst consensus of Hold, with a price target consensus of $39.33.

Adaptimmune Therapeutics (ADAP)

In a report released today, Yanan Zhu from Wells Fargo maintained a Hold rating on Adaptimmune Therapeutics, with a price target of $3.00. The company’s shares closed last Monday at $2.49.

According to TipRanks.com, Zhu is a 1-star analyst with an average return of -10.0% and a 34.3% success rate. Zhu covers the Healthcare sector, focusing on stocks such as Applied Genetic Technologies, Aeglea Biotherapeutics, and Sangamo Biosciences.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Adaptimmune Therapeutics with a $5.25 average price target, which is a 108.3% upside from current levels. In a report issued on November 8, SVB Securities also reiterated a Hold rating on the stock with a $3.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on MRNA:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More